This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
Capital at risk
overfunded
Belluscura
108%
Raised
£542,730
Investors
330
Target
£500,000
Equity
9.67%
Pre-money valuation
£5,067,335

Belluscura has developed the X-PLOR, a lightweight, portable oxygen delivery device aimed at treating the millions of people globally suffering from chronic lung diseases. The company plans to launch this novel and cost-effective device in the US in 2019, with Europe to follow.

  • Planned commercial launch September 2019 into a ₤1.2bn growing market
  • Competitor research suggests X-PLOR can provide 37% more oxygen per kg
  • X-PLOR will be modular allowing a patient to upgrade over time
  • Patents and licenses cover the X-PLOR and broader technologies

Idea

Over 250 million people suffer from Chronic Obstructive Pulmonary Disease (COPD) globally; now the third leading cause of death. COPD is not curable, but patients with COPD are prescribed supplemental oxygen to help relieve shortness of breath and reduce the risk of death. Improving both the mobility of patients and their quality of life is key to living longer, more productive lives.

We have an exclusive license to a patented portable oxygen concentrator (POC), the X-PLOR, that delivers 96% pure oxygen to patients 24/7. The X-PLOR is designed to replace metal oxygen tanks and heavier devices.

Weighing only 1.4kg, X-PLOR is 33% lighter and our research suggests can provide 37% more oxygen per kg than leading competitors. X-PLOR will be both portable, increasing the mobility of people suffering from COPD and price efficient, costing less than tanks over the duration of the disease.

As pollution, smoking and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. Our research suggests that a 3% market share within 3 years could generate £46m in sales.

We plan to expand our proprietary oxygen platform technology into other multi £bn markets such as sleep and wound care. Moreover, we have filed patents on a next-generation portable artificial lung.

We are seeking to raise £500,000 to complete regulatory clearance and launch the X-PLOR in September 2019.

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS.  CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
 
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest.  The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan.  There will be no public offering of the Securities in the United States.
 
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7.  Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear.  Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
 
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.  Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company.  Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
 
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.

To see the rest of the Belluscura pitch, join now.
It’s free, quick and easy.

Join

Already registered? Log in

To see the rest of the Belluscura pitch, join now.
It’s free, quick and easy.

Belluscura

Join to read more information about the Belluscura team, documents, and what other investors are saying about the pitch.

If you choose to invest we won’t take your money until the pitch closes and you can cancel your investment at any time.

Crowdcube is a leading investment crowdfunding platform

Successfully Invested
£689m+
Registered Investors
737k+